Leukemia

Nilotinib and Dasatinib Confer Similar Outcomes for Chronic-Phase CML

Nilotinib and Dasatinib Confer Similar Outcomes for Chronic-Phase CML

By

For patients in the chronic phase of chronic myeloid leukemia, nilotinib and dasatinib showed comparable efficacy as frontline single agents.

Higher-Dose Immunoglobulin Replacement Therapy  in Chronic Lymphocytic Leukemia

Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia

By

Investigators found that dosing of IgRT in CLL at target levels higher than conventional parameters may offer a therapeutic benefit.

Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL

Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL

By

Transplant-naive patients were more likely to achieve an optimal drug response — but were also more prone to severe cytokine release syndrome and neurotoxicity.

Progressive Telomere Shortening: An Epigenetic Biomarker of Chronic Myeloid Leukemia

Progressive Telomere Shortening: An Epigenetic Biomarker of Chronic Myeloid Leukemia

By

Progressive telomere shortening during successive cell divisions is thought to contribute to phase transition in chronic myeloid leukemia.

Harnessing the Power of Both Alemtuzumab and Rituximab in a Bispecific Antibody

Harnessing the Power of Both Alemtuzumab and Rituximab in a Bispecific Antibody

By

Researchers hypothesized that a combination bispecific mAb in B-cell malignancies could offer a treatment option superior to existing monospecific mAbs.

Individualized Lenalidomide Plus Chlorambucil and Rituximab May Be Feasible in Advanced CLL

Individualized Lenalidomide Plus Chlorambucil and Rituximab May Be Feasible in Advanced CLL

By

The feasibility of lenalidomide in combination therapy for chronic lymphocytic leukemia is in question.

Ibrutinib May Be Effective in Patients With Chronic Lymphocytic Leukemia Who Were Excluded from Clinical Trials

Ibrutinib May Be Effective in Patients With Chronic Lymphocytic Leukemia Who Were Excluded from Clinical Trials

By

The RESONATE-2 trial excluded certain patients with chronic lymphocytic leukemia, leaving the efficacy and tolerability of ibrutinib in this population unknown.

Albumin-to-Fibrinogen Ratio May Predict Poor Outcomes in Chronic Lymphocytic Leukemia

Albumin-to-Fibrinogen Ratio May Predict Poor Outcomes in Chronic Lymphocytic Leukemia

By

Albumin-to-fibrinogen ratio may predict poor outcomes in patients with previously untreated chronic lymphocytic leukemia.

Ibrutinib in Chronic Lymphocytic Leukemia Deemed Not Cost-Effective by ICER Standards

Ibrutinib in Chronic Lymphocytic Leukemia Deemed Not Cost-Effective by ICER Standards

By

No direct comparison between ibrutinib and chemoimmunotherapy as a first-line treatment exists.

In Search of the Right Sequence for Venetoclax in CLL

In Search of the Right Sequence for Venetoclax in CLL

By

Researchers reveal the results of the phase 2 CLL2-BAG trial, which evaluated sequential bendamustine followed by obinutuzumab and venetoclax in patients with CLL.

Intensive Chemotherapy May Not Be Effective in MDS or AML After MDS

Intensive Chemotherapy May Not Be Effective in MDS or AML After MDS

By

Researchers sought to determine the impact of intensive chemotherapy on achieving complete remission and overall survival among patients with MDS or sAML.

Time of Response to TKI Therapies May Influence Patient Outcomes in CML

Time of Response to TKI Therapies May Influence Patient Outcomes in CML

By

Early optimal response to TKIs is associated with reductions in treatment failures, poor outcomes, progression of disease, and death.

Second-Generation TKIs May Be Effective After First-Line Imatinib Failure in Pediatric CML

Second-Generation TKIs May Be Effective After First-Line Imatinib Failure in Pediatric CML

By

There is a paucity of data on the use of second-generation tyrosine kinase inhibitors among pediatric patients with chronic-phase chronic myeloid leukemia.

The Real-World Role for Second-Line Ponatinib in CML Is Still Evolving

The Real-World Role for Second-Line Ponatinib in CML Is Still Evolving

By

Perspectives differ on whether ponatinib is a niche drug that should be reserved for younger patients.

FDA Assigns a Breakthrough Therapy Designation to Quizartinib for Relapsed/Refractory FLT3-ITD AML

FDA Assigns a Breakthrough Therapy Designation to Quizartinib for Relapsed/Refractory FLT3-ITD AML

By

Quizartinib — an investigational FLT3 inhibitor — is the first agent in its class to demonstrate improved overall survival.

FDA Approves Ivosidenib for <i>IDH1</i>-Mutated Relapsed/Refractory Acute Myeloid Leukemia

FDA Approves Ivosidenib for IDH1-Mutated Relapsed/Refractory Acute Myeloid Leukemia

By

Ivosidenib is the first-in-class FDA approval for IDH1 mutation-harboring acute myeloid leukemia.

Clinical Stage at First Response May Predict Outcomes in Chronic Lymphocytic Leukemia

Clinical Stage at First Response May Predict Outcomes in Chronic Lymphocytic Leukemia

By

Clinical stage determined by the Binet staging system could be an accurate response surrogate among patients with chronic lymphocytic leukemia.

Research Indicates Imatinib Is Effective in Pediatric Patients With Chronic Phase CML

Research Indicates Imatinib Is Effective in Pediatric Patients With Chronic Phase CML

By

A large, long-term study found a 97% event-free survival rate at 18 months.

2-Year Consolidation with Nilotinib Leads to High Rate of Treatment-Free Remission in CML

2-Year Consolidation with Nilotinib Leads to High Rate of Treatment-Free Remission in CML

By

For the single-treatment STAT2 phase 2 study, researchers enrolled 96 Japanese patients with chronic myeloid leukemia who had achieved a deep molecular response during the consolidation phase of treatment with nilotinib.

Researchers Pinpoint Factors Associated With the Development of Acute Myeloid Leukemia

Researchers Pinpoint Factors Associated With the Development of Acute Myeloid Leukemia

By

Individuals at high risk of developing AML can be identified years before symptoms appear, a new study reports.

Enasidenib Monotherapy May Be Effective in Elderly Patients with IDH2-Mutated AML

Enasidenib Monotherapy May Be Effective in Elderly Patients with IDH2-Mutated AML

By

Investigators sought to evaluate the efficacy of enasidenib among older patients with untreated acute myeloid leukemia, a population that is associated with poor therapeutic outcomes.

Recurrence-Free Survival May Be Sustainable After De-Escalation or Stoppage of TKI Therapy in CML

Recurrence-Free Survival May Be Sustainable After De-Escalation or Stoppage of TKI Therapy in CML

By

Disease recurrence remained low among patients with CML who reduced or discontinued TKI therapy after achieving major response.

Obinutuzumab Plus Chlorambucil May Improve Survival Outcomes in Chronic Lymphocytic Leukemia

Obinutuzumab Plus Chlorambucil May Improve Survival Outcomes in Chronic Lymphocytic Leukemia

By

Researchers randomly assigned previously untreated patients with CD20-positive CLL to receive obinutuzumab plus chlorambucil, rituximab plus chlorambucil, or chlorambucil alone.

In Vitro, In Vivo Studies Show Efficacy of Novel Compound CAR-T Therapy in Acute Myeloid Leukemia

In Vitro, In Vivo Studies Show Efficacy of Novel Compound CAR-T Therapy in Acute Myeloid Leukemia

By

The effect of CAR-T therapy in acute myeloid leukemia has yet to be fully explored.

ENESTfreedom Study Reports Durable Treatment-Free Remission in Chronic Myeloid Leukemia After 96 Weeks

ENESTfreedom Study Reports Durable Treatment-Free Remission in Chronic Myeloid Leukemia After 96 Weeks

By

Nearly half of patients with CML who achieved a deep molecular response following treatment with nilotinib remained in remission for 96 weeks.

Ibrutinib Monotherapy May Improve Survival in Deletion p17 Chronic Lymphocytic Leukemia

Ibrutinib Monotherapy May Improve Survival in Deletion p17 Chronic Lymphocytic Leukemia

By

CLL/SLL characterized by del(17p) — a cytogenetic abnormality that develops over the course of the disease — is difficult to treat and responds very poorly to chemoimmunotherapy.

Bosutinib May Be Effective As First-Line Therapy in Chronic-Phase Chronic Myeloid Leukemia

Bosutinib May Be Effective As First-Line Therapy in Chronic-Phase Chronic Myeloid Leukemia

By

Bosutinib is a dual Src/Abl tyrosine kinase inhibitor approved for newly diagnosed CP-CML and relapsed/refractory CML.

Nilotinib May Lead to Increased Rates of Treatment-Free Remission in Chronic-Phase CML

Nilotinib May Lead to Increased Rates of Treatment-Free Remission in Chronic-Phase CML

By

Data from a previous study supports treatment-free remission as a new treatment goal for patients with chronic-phase chronic myeloid leukemia.

Chronic Myeloid Leukemia and Gastrointestinal Cancer Risk—In the Clinic

Chronic Myeloid Leukemia and Gastrointestinal Cancer Risk—In the Clinic

By

There are some clinical data to support a potential for increased risk of additional solid organ malignancies in patients with CML.

Sex Hormone Levels Significantly Affect Treatment-Free Survival in Chronic Lymphocytic Leukemia

Sex Hormone Levels Significantly Affect Treatment-Free Survival in Chronic Lymphocytic Leukemia

By

Men have approximately double the incidence rate, are more likely to have progressive and treatment-resistant disease, and have a poorer prognosis compared with women with CLL.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs